A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.

Shigehisa KitanoYutaka FujiwaraToshio ShimizuSatoru IwasaKan YonemoriShunsuke KondoAkihiko ShimomuraTakafumi KoyamaTakahiro EbataHiroki IkezawaNozomi HayataYukinori MinoshimaTakuma MiuraTomoki KubotaNoboru Yamamoto

Published in: Cancer chemotherapy and pharmacology (2022)

Clinical Trials.gov number: NCT03006887.

Keyphrases

clinical trial
advanced non small cell lung cancer
phase ii
open label
double blind
study protocol
randomized controlled trial
epidermal growth factor receptor